PURPOSE: To prospectively assess adherence to oncologist-referred, exercise programming consistent with current recommendations for cancer survivors among women with early breast cancer across the trajectory of adjuvant treatment. METHODS: Sixty-eight women participated in supervised, hour-long, moderate-intensity, aerobic, and resistance exercise thrice per week during adjuvant chemotherapy ± radiation, with a step-down in frequency for 20 additional weeks. Adherence to exercise frequency (i.e., attendance), intensity, and time/duration, and barriers to adherence were tracked and compared during chemotherapy versus radiation, and during treatment (chemotherapy plus radiation, if received) versus after treatment. RESULTS: Attendance decreased with cumulative chemotherapy dose (cycles 1-2 vs cycles 3-8, cycle 3 vs cycles 7-8, all P ≤ 0.05) and was lower during chemotherapy than radiation (64% ± 25% vs 71% ± 32%, P = 0.02) and after treatment than during treatment (P < 0.01). Adherence to exercise intensity trended toward being higher during chemotherapy than radiation (69% ± 23% vs 51% ± 38%, P = 0.06) and was higher during than after treatment (P = 0.01). Adherence to duration did not differ with treatment. Overall adherence to the resistance prescription was poor, but was higher during chemotherapy than radiation (57% ± 23% vs 34% ± 39%, P < 0.01) and was not different during than after treatment. The most common barriers to attendance during treatment were cancer-related (e.g., symptoms, appointments), and after treatment were life-related (e.g., vacation, work). CONCLUSIONS: Adherence to supervised exercise delivered in a real-world clinical setting varies among breast cancer patients and across the treatment trajectory. Behavioral strategies and individualization in exercise prescriptions to improve adherence are especially important for later chemotherapy cycles, after treatment, and for resistance exercise.
PURPOSE: To prospectively assess adherence to oncologist-referred, exercise programming consistent with current recommendations for cancer survivors among women with early breast cancer across the trajectory of adjuvant treatment. METHODS: Sixty-eight women participated in supervised, hour-long, moderate-intensity, aerobic, and resistance exercise thrice per week during adjuvant chemotherapy ± radiation, with a step-down in frequency for 20 additional weeks. Adherence to exercise frequency (i.e., attendance), intensity, and time/duration, and barriers to adherence were tracked and compared during chemotherapy versus radiation, and during treatment (chemotherapy plus radiation, if received) versus after treatment. RESULTS: Attendance decreased with cumulative chemotherapy dose (cycles 1-2 vs cycles 3-8, cycle 3 vs cycles 7-8, all P ≤ 0.05) and was lower during chemotherapy than radiation (64% ± 25% vs 71% ± 32%, P = 0.02) and after treatment than during treatment (P < 0.01). Adherence to exercise intensity trended toward being higher during chemotherapy than radiation (69% ± 23% vs 51% ± 38%, P = 0.06) and was higher during than after treatment (P = 0.01). Adherence to duration did not differ with treatment. Overall adherence to the resistance prescription was poor, but was higher during chemotherapy than radiation (57% ± 23% vs 34% ± 39%, P < 0.01) and was not different during than after treatment. The most common barriers to attendance during treatment were cancer-related (e.g., symptoms, appointments), and after treatment were life-related (e.g., vacation, work). CONCLUSIONS: Adherence to supervised exercise delivered in a real-world clinical setting varies among breast cancerpatients and across the treatment trajectory. Behavioral strategies and individualization in exercise prescriptions to improve adherence are especially important for later chemotherapy cycles, after treatment, and for resistance exercise.
Authors: Kelcey A Bland; Sarah E Neil-Sztramko; Amy A Kirkham; Alis Bonsignore; Cheri L Van Patten; Donald C McKenzie; Karen A Gelmon; Kristin L Campbell Journal: Support Care Cancer Date: 2018-04-13 Impact factor: 3.603
Authors: Ryan J Marker; Emily Cox-Martin; Catherine M Jankowski; W Thomas Purcell; John C Peters Journal: Support Care Cancer Date: 2017-12-21 Impact factor: 3.603
Authors: Erik D Hanson; Lauren C Bates; Elizabeth P Harrell; David B Bartlett; Jordan T Lee; Chad W Wagoner; Mohamdod S Alzer; Dean J Amatuli; Brian C Jensen; Allison M Deal; Hyman B Muss; Kirsten A Nyrop; Claudio L Battaglini Journal: Exp Gerontol Date: 2021-06-16 Impact factor: 4.253
Authors: Amy A Kirkham; D Ian Paterson; Carla M Prado; John R Mackey; Kerry S Courneya; Edith Pituskin; Richard B Thompson Journal: BMC Cancer Date: 2018-09-03 Impact factor: 4.430
Authors: Jordan T Lee; Chad W Wagoner; Stephanie A Sullivan; Dean J Amatuli; Kirsten A Nyrop; Erik D Hanson; Lee Stoner; Brian C Jensen; Hyman B Muss; Claudio L Battaglini Journal: World J Clin Oncol Date: 2021-06-24
Authors: Jonna K VAN Vulpen; Maike G Sweegers; Petra H M Peeters; Kerry S Courneya; Robert U Newton; Neil K Aaronson; Paul B Jacobsen; Daniel A Galvão; Mai J Chinapaw; Karen Steindorf; Melinda L Irwin; Martijn M Stuiver; Sandi Hayes; Kathleen A Griffith; Ilse Mesters; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Martina E Schmidt; Cornelia M Ulrich; Marc VAN Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H VAN Harten; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem VAN Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Irma M Verdonck-DE Leeuw; Johannes Brug; Anne M May; Laurien M Buffart Journal: Med Sci Sports Exerc Date: 2020-02